Bio-Path Holdings Announces Publication in Biomedicines
Bio-Path Holdings (NASDAQ:BPTH) announced a publication in Biomedicines highlighting the therapeutic potential of BP1003 in various cancer types. The article, titled 'BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment,' describes the broad anti-tumor effect of BP1003 in preclinical solid tumor models including breast, ovarian, and pancreatic cancer.
BP1003 is a neutral liposome incorporated with a nuclease resistant P-ethoxy antisense oligodeoxynucleotide targeting the STAT3 mRNA. The company believes BP1003 has the potential to enhance the efficacy of current standard of care chemotherapies in a broad range of difficult to treat cancers. This publication marks Bio-Path's twenty-second peer-reviewed article supporting its DNAbilize® technology.
Bio-Path Holdings (NASDAQ:BPTH) ha annunciato la pubblicazione in Biomedicines che evidenzia il potenziale terapeutico di BP1003 in vari tipi di cancro. L'articolo, intitolato 'BP1003 Riduce l'Espressione di STAT3 e Le Sue Funzioni Pro-Tumorigeniche nei Tumori Solidi e nel Microambiente Tumorale,' descrive il ampio effetto anti-tumorale di BP1003 in modelli preclinici di tumori solidi, inclusi cancro al seno, ovarico e pancreatico.
BP1003 è un liposoma neutro incorporato con un oligonucleotide antisense P-etossido resistente alle nucleasi che mira all'mRNA di STAT3. L'azienda crede che BP1003 abbia il potenziale di migliorare l'efficacia delle attuali terapie chemioterapiche standard in un'ampia gamma di cancri difficili da trattare. Questa pubblicazione segna il ventiduesimo articolo sottoposto a revisione paritaria di Bio-Path a sostegno della sua tecnologia DNAbilize®.
Bio-Path Holdings (NASDAQ:BPTH) anunció una publicación en Biomedicines que resalta el potencial terapéutico de BP1003 en varios tipos de cáncer. El artículo, titulado 'BP1003 Disminuye la Expresión de STAT3 y Sus Funciones Pro-Tumorigénicas en Tumores Sólidos y el Microambiente Tumoral,' describe el amplio efecto anti-tumoral de BP1003 en modelos preclínicos de tumores sólidos, incluyendo cáncer de mama, de ovario y pancreático.
BP1003 es un liposoma neutro incorporado con un oligonucleótido antisense P-etóxido resistente a nucleasas que tiene como objetivo el ARNm de STAT3. La compañía cree que BP1003 tiene el potencial de aumentar la eficacia de las quimioterapias estándar actuales en una amplia gama de cánceres difíciles de tratar. Esta publicación marca el vigésimo segundo artículo revisado por pares de Bio-Path que apoya su tecnología DNAbilize®.
Bio-Path Holdings (NASDAQ:BPTH)는 다양한 암 유형에서 BP1003의 치료 가능성을 강조하는 Biomedicines에 논문을 발표했습니다. 'BP1003가 고형 종양과 종양 미세 환경에서 STAT3 발현과 그 친종양 기능을 감소시킴'이라는 제목의 이 기사에서는 유방암, 난소암, 췌장암을 포함한 전임상 고형 종양 모델에서 BP1003의 광범위한 항종양 효과를 설명합니다.
BP1003는 중성 리포좀으로, STAT3 mRNA를 표적으로 하는 핵산 분해 효소 저항성 P-에톡시 항센스 올리고데옥시뉴클레오타이드가 포함되어 있습니다. 회사는 BP1003가 치료가 어려운 다양한 암의 현재 표준 치료 화학요법의 효능을 높일 수 있는 잠재력이 있다고 믿고 있습니다. 이 출판물은 Bio-Path의 22번째 동료 검토 논문으로, DNAbilize® 기술을 지원합니다.
Bio-Path Holdings (NASDAQ:BPTH) a annoncé une publication dans Biomedicines mettant en évidence le potentiel thérapeutique de BP1003 dans divers types de cancer. L'article, intitulé 'BP1003 Diminue l'Expression de STAT3 et ses Fonctions Pro-Tumorigènes dans les Tumeurs Solides et le Microenvironnement Tumoral,' décrit le large effet anti-tumoral de BP1003 dans des modèles précliniques de tumeurs solides, y compris le cancer du sein, de l'ovaire et du pancréas.
BP1003 est un liposome neutre incorporé avec un oligonucléotide antisens P-éthoxy résistant aux nucléases ciblant l'ARNm de STAT3. L'entreprise croit que BP1003 a le potentiel d'améliorer l'efficacité des chimiothérapies standard actuelles dans un large éventail de cancers difficiles à traiter. Cette publication marque le vingt-deuxième article évalué par des pairs de Bio-Path soutenant sa technologie DNAbilize®.
Bio-Path Holdings (NASDAQ:BPTH) hat eine Veröffentlichung in Biomedicines angekündigt, die das therapeutische Potenzial von BP1003 bei verschiedenen Krebsarten hervorhebt. Der Artikel mit dem Titel 'BP1003 verringert die STAT3-Expression und deren pro-tumorigenische Funktionen in soliden Tumoren und der Tumormikroumgebung' beschreibt die breite antitumorale Wirkung von BP1003 in präklinischen Modellen solider Tumoren, einschließlich Brust-, Eierstock- und Bauchspeicheldrüsenkrebs.
BP1003 ist ein neutrales Liposom, das mit einem nukleasenresistenten P-Ethoxy-Antisense-Oligodeoxynukleotid ausgestattet ist, das auf das STAT3-mRNA abzielt. Das Unternehmen ist der Ansicht, dass BP1003 das Potenzial hat, die Wirksamkeit der aktuellen Standard-Chemotherapien bei einer breiten Palette von schwer behandelbaren Krebserkrankungen zu verbessern. Diese Veröffentlichung markiert den 22. peer-reviewed Artikel von Bio-Path zur Unterstützung seiner DNAbilize®-Technologie.
- Publication in peer-reviewed journal Biomedicines highlighting BP1003's therapeutic potential
- BP1003 shows broad anti-tumor effect in preclinical solid tumor models
- Potential to enhance efficacy of current standard chemotherapies in difficult to treat cancers
- Twenty-second peer-reviewed publication supporting DNAbilize® technology
- None.
The publication in Biomedicines highlighting BP1003's therapeutic potential is a significant milestone for Bio-Path Holdings. This peer-reviewed article adds credibility to their DNAbilize® technology and expands its potential applications. The study's focus on BP1003's efficacy in multiple solid tumor models, including breast, ovarian and pancreatic cancers, broadens the drug's market potential.
The targeting of STAT3 mRNA is particularly noteworthy. STAT3's role in tumorigenesis, drug resistance and immune evasion makes it a prime target for cancer therapeutics. If BP1003 can effectively inhibit STAT3, it could potentially address multiple challenges in cancer treatment simultaneously. The suggestion that BP1003 might enhance the efficacy of current chemotherapies is especially promising, as combination therapies are increasingly important in oncology.
However, it's important to note that these are still preclinical results. The transition from preclinical to clinical success is notoriously challenging in oncology. Investors should watch for announcements of clinical trials to gauge BP1003's true potential.
This publication marks Bio-Path's 22nd peer-reviewed article supporting their DNAbilize® technology, demonstrating a consistent track record of scientific validation. This accumulation of evidence could be important for attracting partnerships or funding for future clinical trials.
The company's pipeline diversity is noteworthy. With prexigebersen in Phase 2 for blood cancers, BP1001-A in Phase 1/1b for solid tumors and BP1002 being evaluated for both blood cancers and solid tumors, Bio-Path is not overly reliant on a single candidate. The addition of BP1003, targeting STAT3, further diversifies their portfolio.
However, Bio-Path's market cap and stock performance suggest investor skepticism. The company will need to show clinical progress and potentially seek strategic partnerships to fully capitalize on their pipeline's potential. The planned IND filing for BP1003 could be a near-term catalyst, but investors should be aware that the path from IND to market is long and uncertain in biotech.
Manuscript Highlights Therapeutic Potential of BP1003 in Variety of Cancers
Marks Company’s Twenty-Second Peer-Reviewed Publication in Support of its DNAbilize® Technology
HOUSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced a publication highlighting the therapeutic potential of BP1003 in a variety of cancer types in the peer-reviewed journal, Biomedicines.
The article, titled “BP1003 Decreases STAT3 Expression and Its Pro-Tumorigenic Functions in Solid Tumors and the Tumor Microenvironment,” describes the broad anti-tumor effect of BP1003 in numerous preclinical solid tumor models including breast, ovarian, and pancreatic cancer. BP1003 is a neutral liposome incorporated with a nuclease resistant P-ethoxy antisense oligodeoxynucleotide targeting the STAT3 mRNA and its unique design enhances stability, cellular uptake, and target affinity.
The article was authored by Maria Gagliardi, Ph.D., Senior Research Scientist, Michael Roberts, Director of Manufacturing Planning & Engineering, and Ana Tari Ashizawa, Ph.D., Senior Vice President of Research, Development and Clinical Design at Bio-Path Holdings. The article’s co-authors included investigators from Thomas Jefferson University and University of Texas MD Anderson Cancer Center.
“Overexpression and aberrant activation of STAT3 contributes to tumorigenesis, drug resistance, and tumor-immune evasion, making it a probable cancer therapeutic target. Consequently, we believe BP1003 has the potential to enhance the efficacy of current standard of care chemotherapies in a broad range of difficult to treat cancers,” said Dr. Tari Ashizawa.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, that patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10-K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at www.sec.gov. Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369
FAQ
What is the therapeutic potential of BP1003 according to the Biomedicines publication?
How does BP1003 target cancer cells?
What is the significance of this publication for Bio-Path Holdings (BPTH)?
What other product candidates does Bio-Path Holdings (BPTH) have in its pipeline?
